Strosberg, Jonathan

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 3,308

177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J. (2019) · Expert Review of Gastroenterology & Hepatology

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 135

Phase II Clinical Trial of Pasireotide Long-Acting Repeatable in Patients with Metastatic Neuroendocrine Tumors

Cives, M., Kunz, P. L., Morse, B., Coppola, D., Schell, M. J., Campos, T., Nguyen, P. T., Nandoskar, P., Khandelwal, V, & Strosberg, J. R. (2015) · Endocrine-Related Cancer

Neuroendocrine Tumor Research AdvancesPituitary Gland Disorders and Treatments

Cited by 96

Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms.

Tafreshi, N. K., Pandya, D. N., Tichacek, C. J., Budzevich, M. M., Wang, Z., Reff, J. N., Engelman, R. W., Boulware, D. C., Chiappori, A. A., Strosberg, J. R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Radiopharmaceutical Chemistry and ApplicationsNeuroendocrine Tumor Research Advances

Cited by 50